Kidney 11β-HSD2 is inhibited by glycyrrhetinic acid-like factors in human urine

Hypertension

Volumn 29, Issue 1 II, 1997, Pages 500-505

  Lo, Ying H ^c   Sheff, Michael F ^c   Latif, Syed A ^c   Ribeiro, Carla ^c   Silver, Helene ^a   Brem, Andrew S ^a   Morris, David J ^b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c NONE

Author keywords

GALF; glycyrrhetinic acid; hydroxysteroid dehydrogenase; licorice; pregnancy; urine

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; GLYCYRRHETINIC ACID; GLYCYRRHETINIC ACID DERIVATIVE; ISOENZYME;

ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ENZYME INACTIVATION; FEMALE; GLYCYRRHIZA; HUMAN; HYPERTENSION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RAT; URINALYSIS; VASCULAR SMOOTH MUSCLE;

EID: 0031035845     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.29.1.500     Document Type: Article

References (31)

1. Morris DJ, Semafuko WEB, Latif SA, Grimes CA, Sheff MF. Detection of glycyrrhetinic acid-like factors (GALFs) in human urine. Hypertension. 1992;20:356-360.
2. Ulick S, Levine LS, Gunczler P, Zancoato G, Ramirez LC, Rauh W, Rosler A, Bradlow HL, New MI. A syndrome of apparent mineralocorticoid excess associated with defects in peripheral metabolism on cortisol. J Clin Endocrinol Metab. 1979;49:757-764.
3. New MI, Oberfeld SE, Carey R, Grieg F, Ulick S, Levine LS. A genetic defect in cortisol metabolism as the basis for the syndrome of apparent mineralocorticoid excess syndrome. In: Mantero F, Biglieri C, Edwards CWR, eds. Endocrinology of Hypertension. New York NY: Academic Press; 1982:85-101.
4. Monder C, Shackleton CHL, Bradlow HL, New MI, Stoner E, Iohan F, Lakshmi V. The syndrome of apparent mineralocorticoid excess: its association with 11β-dehydrogenase and 5β-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab. 1986;62:550-557.
5. Oberfeld SE, Levine RM, Carvey RM, Greig F, Ulick S, New MI. Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1983;56:332-339.
6. Edwards CRW, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, Dekloet ER, Monder C. Localization of 11β-hydroxysteroid dehydrogenase: tissue specific protector of the mineralocorticoid receptor. Lancet. 1988;2:986-989.
7. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue is enzyme not receptor mediated. Science. 1988;242: 583-585.
8. Semafuko WEB, Sheff MF, Grimes C, Latif SA, Sadaniantz A, Levinson P, Morris DJ. Inhibitors of 11β-hydroxysteroid dehydrogenase and 5β-steroid reductase (GALFs) in urine from patients with congestive heart failure. Ann Clin Lab Sci. 1993;23:456-461.
9. Monder C, White PC. 11β-Hydroxysteroid dehydrogenase. Vitamins Hormones. 1993;47:187-269.
10. Naray-Fejes-Toth A, Watlington CO, Fejes-Toth G. 11β-Hydroxysteroid activity in the renal target cells of aldosterone. Endocrinology. 1991;129:17-21.
11. Rusvai E, Naray-Fejes-Toth A. A new isoform of 11β-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem. 1993;268:1-4.
12. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CHL, Funder JW, New MI. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995;80:2263-2266.
13. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet. 1995;10:394-399.
14. +-dependent isoform of 11β-hydroxysteroid dehydrogenase: cloning and characterization of cDNA from sheep kidney. J Biol Chem. 1994; 269:25959-25962.
15. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol. 1994;105:R11-R17.
16. Latif SA, Sheff MF, Ribeiro CE, Morris DJ. 11β-Hydroxysteroid dehydrogenase (11β-HSD) isoform 2 from sheep kidney is selectively inhibited by 5α-metabolites (but not 5β-metabolites of adrenal cortex). Steroids. In press.
17. Brem AS, Bina B, King T, Morris DJ. Bidirectional activity of 11β-hydroxysteroid dehydrogenase in vascular smooth muscle cells. Steroids. 1995;20:406-410.
18. Stewart PM, Valentino R, Wallace AM, Burt D, Shackleton CHL, Edwards CRW. Mineralocorticoid activity of licorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987;2: 821-824.
19. Souness GW, Morris DJ. The antinatriuretic and kaliuretic effects of corticosterone and cortisol following pretreatment with carbenoxolone sodium (a liquorice derivative) in the adrenalectomized rat. Endocrinology. 1989;124:1588-1590.
20. Souness GW, Morris DJ. The 'mineralocorticoid-like' actions conferred on corticosterone by carbenoxolone are inhibited by the mineralocorticoid receptor (type I) antagonist RU28318. Endocrinology. 1991;129:2451-2456.
21. + retention. Steroids. 1994;59:352-356.
22. Souness GW, Latif SA, Laurenzo JL, Morris DJ. 11α- and 11β-Hydroxyprogesterone, potent inhibitors of 11β-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat. Endocrinology. 1995;136:1809-1812.
23. Souness GW, Morris DJ. 11α- and 11β-Hydroxyprogesterone, potent inhibitors of 11β-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat. Hypertension. 1996;27:421-425.
24. Walker BR, Connacher AA, Webb DJ, Edwards CRW. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clin Sci. 1992;83:171-178.
25. Krozowski Z, Maguire JA, Stein-Oakly AN, Dowling J, Smith RE, Andrews RK. Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab. 1995;80:2203-2209.
26. Ullian ME, Walsh LG. Corticosterone metabolism and effects on angiotensin II receptors in vascular smooth muscle. Circ Res. 1995;77:702-709.
27. Takeda Y, Miyamori I, Iki K, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, Takeda R. Endogenous renal 11β-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension. Hypertension. 1996;27:197-201.
28. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in subjects with untreated essential hypertension. Hypertension. 1995;25:67-70.
29. Kornel L, Starnes WR, Hill SR Jr, Hill A. Studies on steroid conjugates, VI: quantitative paper chromatography of urinary corticostefoids in essential hypertension. J Clin Endocrinol Metab. 1969; 29:1608-1617.
30. Kornel L, Margolis E. Evidence for overall deficiency of cortisol 11β-hydroxy dehydrogenase in patients with essential hypertension. In: Proceedings of the 9th International Congress of Endocrinology. September 1992; Nice, France. Abstract P-04.31.123; 142.
31. Walker BR, Williamson PM, Brown MA, Honour JW, Edwards CRW, Whitworth JA. 11β-Hydroxysteroid dehydrogenase and its inhibitors in hypertensive pregnancy. Hypertension. 1994;25:626-630.